<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="4">
  <stage>Registered</stage>
  <submitdate>8/07/2005</submitdate>
  <approvaldate>18/07/2005</approvaldate>
  <actrnumber>ACTRN12605000021673</actrnumber>
  <trial_identification>
    <studytitle>Effects of natural seaweed extract (GFS) on mobilisation of human bone marrow stem cells and immune system activation</studytitle>
    <scientifictitle>A randomised phase II study to evaluate the effects of natural seaweed extract (GFS) in normal volunteers on mobilising stem cells and activating the immune system.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Normal volunteers</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The aim of this study is to look at the effects of ingesting seaweed fucoidan (GFS) on the mobilisation/release of haematopoeitic progenitor stem cells from bone marrow to the peripheral blood and to study its effects on modulating the immune system. This will be important in treatment following autologous transplantation, AIDS and cancer patients.

Investigational Arms:
1. 3g of 10% GFS/Day for 12 days
2.  3g of 75% GFS/Day for 12 days
3. G-CSF treatment</interventions>
    <comparator>Control arm:
3g of placebo fibers (guar gum) for 12 days</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the effects of GFS (fucoidan) on the mobilization of haematopoietic progenitor stem cells</outcome>
      <timepoint>After 12 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To evaluate the effects of GFS (fucoidan) on the immune system modulation</outcome>
      <timepoint>After 12 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To evaluate the effects of GFS (fucoidan) on the level of SDF-1 in healthy subjects before and affter G-CSF treatment</outcome>
      <timepoint>After 12 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>N/A</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Volunteers criteria:Healthy adults, non-smokers, no treatment in the last 30 days including contraceptive pills, no history of thyroid abnormalities, no sulpher allergy. Withdrawal criteria:development of thyroid abnormalities, volunteer requestG-CSF subjects:normal adult subjects, suitable for G-CSF treatment, about to recieve G-CSF</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/01/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>UTas</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Tasmania</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mohammad Irhimeh</name>
      <address>43 Collins St
Hobart 7001 TAS</address>
      <phone>+61 3 62264846</phone>
      <fax>+61 3 62264894</fax>
      <email>mirhimeh@utas.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mohammad Irhimeh</name>
      <address>43 Collins St
Hobart TAS 7001</address>
      <phone>+61 3 62264846</phone>
      <fax>+61 3 62264894</fax>
      <email>mirhimeh@utas.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>